Clinical evidence dossier
Pioglitazone
HbA1c
Evidence signal
Authoritative evidence signal
strong
This is an authoritative evidence signal supplied by Clinical Reference. It is not a formal clinical grade, treatment recommendation, or pooled effect estimate.
Evidence snapshot
- Authoritative support records
- 5
- Supporting studies available for review
- 5
- Randomized trials
- 5
- Reported effects
- 15
Clinical conclusion
Pioglitazone shows a strong positive evidence signal for improving HbA1c across the studied comparisons.
Observed effects
Observed study estimates; not a pooled treatment effect.
Change from baseline
Absolute change
-1.3 to -0.81 %
Change from baseline
Mean difference
-0.93 to 0 %
Evidence composition
- Non-randomized studies
- 0
- Other designs
- 0
- Unresolved designs
- 0
- Magnitude-eligible effects
- 10
Consistency
Authoritative consistency classification
consistent
- Positive
- 5
- No effect
- 0
- Mixed
- 0
- Negative
- 0
Population and applicability
Structured population data were available for 5 of 5 supporting studies. 5 studies described participants with type 2 diabetes. 5 studies described adult participants.
This population information refers to the materialized supporting studies available for review. Omitted support records remain part of the authoritative support accounting and are available through the audit experience.
View reported population descriptions
These descriptions are reported across the supporting studies; they are not a single synthesized population.
- Adults diagnosed with type 2 diabetes
- Patients currently on metformin and DPP-4 inhibitors
- Adults diagnosed with type 2 diabetes mellitus.
- Patients with non-alcoholic fatty liver disease (NAFLD).
- Adults diagnosed with type 2 diabetes.
- Patients experiencing metabolic dysfunction-associated steatotic liver disease.
- Adults with type 2 diabetes inadequately controlled on metformin and empagliflozin.
- Patients seeking additional therapy options for glycemic control.
- Adults diagnosed with Type 2 Diabetes.
- Patients with metabolic dysfunction-associated steatotic liver disease.
Limitations
- Evidence uses heterogeneous comparison contexts: active_comparator, baseline_within_group, placebo.
Supporting evidence
Inspect the authoritative studies and omitted support records for this dossier.